Alvarez Pedro, Hee Christopher K, Solchaga Luis, Snel Leo, Kestler Hans K, Lynch Samuel E, Hollinger Jeffrey O
Department of Biomedical Engineering and Bone Tissue Engineering Center, Carnegie Mellon University, Pittsburgh Technology Center, Pittsburgh, Pennsylvania 15219, USA.
J Craniofac Surg. 2012 Jan;23(1):20-9. doi: 10.1097/SCS.0b013e318240c6a8.
The specialty of craniofacial surgery is broad and includes trauma, aesthetics, reconstruction of congenital deformities, and regeneration of tissues. Moreover, craniofacial surgery deals with a diverse range of tissues including both "soft" and "hard" tissues. Technological advances in materials and biological sciences and improved surgical techniques have remarkably improved clinical outcomes. The quest to raise the bar for patient care continues to inspire advances for predictable biological regeneration of soft and hard tissues. As a consequence of this quest for advancement, a wide spectrum of biologicals is becoming available to surgeons. Is the use of recombinant DNA engineered biologicals daring? Sensible? Logical? Timely? Safe? It is crucial for the practicing craniofacial surgeon to take a step back periodically and carefully review the biological factors that have the potential for dramatically altering the discipline of craniofacial surgery. With this emphasis, the coauthors of this article will focus on growth factor technology underscoring bone tissue regeneration. As the 21st-century matures, recombinant human biologicals will have an overwhelming impact on the practice of craniofacial surgery.
颅面外科专业范围广泛，包括创伤、美学、先天性畸形的重建以及组织再生。此外，颅面外科涉及多种组织，包括“软组织”和“硬组织”。材料科学和生物科学的技术进步以及手术技术的改进显著改善了临床疗效。提高患者护理标准的追求继续推动软组织和硬组织可预测生物再生方面的进展。由于这种追求进步的努力，外科医生可以获得各种各样的生物制剂。使用重组DNA工程生物制剂是大胆的？明智的？合乎逻辑的？适时的？安全的？对于执业颅面外科医生来说，定期退后一步，仔细审视那些有可能极大改变颅面外科领域的生物因素至关重要。基于这一重点，本文的共同作者将聚焦于强调骨组织再生的生长因子技术。随着21世纪的成熟，重组人生物制剂将对颅面外科的实践产生压倒性影响。
